North Bergen, New Jersey--(Newsfile Corp. - October 9, 2025) -  Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), is pleased to announce that it has completed the first step in the closing process with Revive Regenerative, Inc. The Company has secured the initial tranche of capital required in the amount of $500,000 as set forth in the merger agreement. In addition, the Company has finalized with GSS Capital to raise the additional $3,000,000 needed, with the terms agreed to by both sides. The partie ...

Core Insights - U.S.-listed biotech and healthcare stocks experienced significant bullish activity in after-hours trading, with Turn Therapeutics Inc. leading the surge with a 134.29% increase to $16.40 following its Nasdaq debut [1] Group 1: Company Performances - Talphera Inc. reached a new 52-week high in regular trading and added 4.55% after hours to close at $1.38, driven by momentum despite no new updates [2] - Personalis Inc. rose 1.50% to $8.81 in after-hours trading, having hit a 52-week high earlier in the day, likely due to ongoing investor interest in precision oncology [2] - Ionis Pharmaceuticals Inc. climbed 3.64% to $72.51 after hours, supported by its Innovation Day presentation and reaffirmation of its pipeline strategy, leading to a new 52-week high during regular trading [3] - Sensei Biotherapeutics Inc. increased 5.23% to $12.08, with anticipation building ahead of its pipeline updates scheduled for October 20 [3] - Corbus Pharmaceuticals Holdings Inc. gained 4.77% to $14.06, preparing for participation in the Piper Sandler Virtual Oncology Symposium on October 9 [4] - Longeveron Inc. advanced 5.71% to $0.9801, with expectations for insights into its regenerative medicine pipeline at the ROTH Healthcare Opportunities Conference [4] - Palisade Bio Inc. rose 5.00% to $2.10 in after-hours trading, buoyed by a recent $138 million public offering that strengthened its balance sheet ahead of Phase 2 trials [5] Group 2: Market Trends - The after-hours session showcased a mix of technical breakouts, event-driven anticipation, and momentum trading, indicating a fertile environment for volatility and investment opportunities in the biotech sector [6]

North Bergen, New Jersey--(Newsfile Corp. - October 8, 2025) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), is pleased to announce that it has re-engaged GSS Capital, a licensed Investment Bank and a member of FINRA, for advisory services to assist in the restructuring of the Company's Balance Sheet, coordinate the conversion of all convertible and secured debt of the Company to allow the Company to comply with the conditions of the Letter of Intent with Revive Regenerative, Inc. They will also ...

Adia Nutrition Inc. Divests Biolete Coffee Subsidiary to Cement Factory LLC, Retains 18% Ownership to Support Strategic Focus on Regenerative Medicine and Medical SalesOctober 06, 2025 12:39 PM EDT | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - October 6, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine and innovative healthcare solutions, today announced the sale of its Biolete coffee subsidiary to Cement Factory LLC, a dynamic consu ...

Combat Sports Partnership Brings Advanced Stem Cell Treatments to Elite Fighters LAS VEGAS, NEVADA / ACCESS Newswire / September 29, 2025 / Regenerative Medical Technologies Group, Inc. (the "Company") (OTCID:RMTG), a global leader in regenerative medicine solutions, announces a new strategic partnership with Bare Knuckle Fighting Championship (BKFC) to serve as the league's official stem cell and regenerative medicine provider for treating fighters' sport-related injuries. Why Fighters Need These Treatment ...

Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpointStatistically significant maintenance of function (p<0.0001)Company will request pre-BLA meeting with FDA to discuss submission pathway CANTON, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the ...

On-demand programs deliver clinically relevant science, technical instruction, and case applications in small animal and equine practice MINNEAPOLIS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, a subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and a veterinary medical device company pioneering intra-articular and regenerative solutions, announces the launch of three new continuing education (CE) courses for veterinary professionals. Each RACE-approved program (1.0 credit hour) ...

Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsClear regulatory pathway following positive Type B meeting with U.S. FDAFDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease MIAMI, Sept. 22, 2025 (GLOBE NEWSWIRE) ...

Core Viewpoint - Kelyniam Global, Inc. has received FDA 510(k) clearance for its Fusion Cranial and Craniofacial Implants, marking a significant advancement in implant technology and the first approval of its kind in 8 years [1][2]. Company Overview - Kelyniam Global, Inc. specializes in custom cranial and craniofacial implants, utilizing biocompatible materials to provide patient-specific solutions with rapid turnaround times [4]. Product Details - The Fusion BCP-PEEK implants are made from a unique combination of Biphasic Calcium Phosphate (BCP) reinforced with Polyether Ether Ketone (PEEK), designed to encourage bone integration and provide exceptional durability [1][3]. - These implants are tailored for specific neurosurgery needs, addressing traumatic injuries, tumor resections, and congenital anomalies, and can be designed and shipped within 24-48 hours [3]. Market Impact - The FDA clearance represents a milestone in the cranial and craniofacial implant market, as it is the first new implant introduced in 8 years, highlighting Kelyniam's innovative capabilities [2][3].

Core Insights - FibroBiologics is advancing its IND-enabling preclinical development for psoriasis treatment using human dermal fibroblast (HDF) spheroids, showing promising results in reducing disease recurrence [1][5] - The company aims to provide durable and scalable solutions for chronic inflammatory diseases, addressing a significant market need [2][5] Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing therapeutics and potential cures for chronic diseases through fibroblast science [9] - The company holds over 270 patents issued and pending, covering various clinical pathways including psoriasis, wound healing, and cancer [9] Research and Development - In an acute psoriasis model, a single administration of HDF spheroids demonstrated efficacy comparable to multiple doses of an anti-IL-23 monoclonal antibody [3] - Ongoing research includes exploring repeated dosing regimens, cytokine profiling, and histopathological assessments to enhance understanding of treatment mechanisms [4] Market Opportunity - Chronic inflammatory diseases represent a massive, underserved market, and FibroBiologics sees an opportunity to lead in this space by focusing on durability, safety, and reproducibility of treatments [5] - The company is evaluating the potential for a single HDF spheroid treatment to provide long-term protection against psoriasis relapse, which could revolutionize treatment approaches [5]